Zhejiang Langhua Pharmaceutical is a contract manufacturer based in China. It holds 3 active US drug master files and 3 valid CEPs across a filed portfolio of 5 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 30 August 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Linhai, China | Not on file |
| China, China | 3005289386 |
| Molecule | Regulators | Docs |
|---|---|---|
| Levofloxacin | EDQM, US FDA | 2 |
| Spironolactone | EDQM, US FDA | 2 |
| Empagliflozin | US FDA | 1 |
| Enrofloxacin For Veterinary Use | EDQM | 1 |
| Ibrutinib | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Langhua Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free